OTCBB ALERTS

[Pastor Phil]

DEEP BLUE INC. DPBL

Deep Blue, Inc. (PINKSHEETS: DPBL)

There are approximately 1 million people in North America living with HIV at present; with a 15% market penetration our treatment protocols would provide gross receipts of $3.75 billion per annum. Additionally, in this market there are 44,000 new cases of HIV each year. Even if only 15% of newly diagnosed cases participated, with fees of $25,000 per patient, the additional revenue would be approximately $165,000,000 per year.

The number of patients treatable per day depends on the size and availability of the hyperbaric chamber. For our baseline analysis, we will use a state of the art 24-patient multi-place class "A" chamber, with 16 hours each day for scheduled use. Under these parameters, 240 patients per day could be treated per facility and Deep Blue could feasibly treat 140 such groups or approximately 3,300 patients at each facility in one year. This would equate to gross receipts per facility of over $80,000,000 per year.

Deep Blue, Inc. (www.deepblueinc.com) is bringing to market an innovative patent-pending treatment, (Application Number 11/208,402), for HIV/AIDS and other viral infectious diseases.